CIBC Asset Management
MRSN

CIBC Asset Management’s Mersana Therapeutics MRSN Stock Holding History

CIBC Asset Management’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-19,067
Closed -$1.96M – 1111
2023
Q1 		$1.96M Sell
19,067
-3,604
-16% -$506K 0.01% 560
2022
Q4 		$3.32M Buy
+22,671
New +$3.83M 0.01% 436
2022
Q2 		– Sell
-42,240
Closed -$4.21M – 1400
2022
Q1 		$4.21M Hold
42,240
– – 0.01% 390
2021
Q4 		$6.57M Sell
42,240
-112
-0.3% -$21.8K 0.02% 333
2021
Q3 		$9.98M Buy
42,352
+12
+0% +$3.51K 0.04% 234
2021
Q2 		$14.4M Buy
42,340
+29,235
+223% +$11.1M 0.06% 183
2021
Q1 		$5.3M Buy
+13,105
New +$6.36M 0.02% 318

Other funds holding MRSN

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

CIBC Asset Management's MRSN Position: Q2 2023 in Review

CIBC Asset Management sold out of Mersana Therapeutics (MRSN) in Q2 2023, closing a stake of 19,067 shares — an estimated $1.96M sold.

CIBC Asset Management first reported a position in MRSN in Q1 2021 and held it in 7 quarters. The position peaked at $14.4M in Q2 2021. 147 funds tracked by Wall St. Rank hold MRSN as of Q2 2023.

  • CIBC Asset Management reported no remaining Mersana Therapeutics position as of Q2 2023 after selling out during the quarter.
  • CIBC Asset Management sold 19,067 Mersana Therapeutics shares in Q2 2023, an estimated $1.96M.
  • CIBC Asset Management first reported a position in Mersana Therapeutics in Q1 2021 and held it in 7 quarters.
  • CIBC Asset Management's Mersana Therapeutics position peaked at $14.4M in Q2 2021.
  • 147 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q2 2023.

Based on CIBC Asset Management's 13F filing for Q2 2023, filed 14 Aug 2023.